Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
100 participants
Apr 21, 2026
INTERVENTIONAL
Conditions
Summary
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
Eligibility
Inclusion Criteria5
- Participants with histologically or cytologically confirmed ES-SCLC.
- Fully understand the study and voluntarily sign the informed consent form;
- Male or female 18~75 years of age;
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
- Life expectancy ≥ 3 months;
Exclusion Criteria1
- Participants were deemed unsuitable for participating in the study by the investigator for any reason.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ZG006 will be administered as an IV infusion.
Serplulimab will be administered as an IV infusion.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07231445